Rebamipide

Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer[1][2].

Product Specifications

CAS Number

[90098-04-7]

Product Name Alternative

OPC12759; Proamipide

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rebamipide.html

Purity

99.94

Solubility

DMSO : 25 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

OC(C(NC(C1=CC=C(Cl)C=C1)=O)CC(C2=CC=CC=C2N3)=CC3=O)=O

Molecular Formula

C19H15ClN2O4

Molecular Weight

370.79

Precautions

H302, H315, H319, H335

References & Citations

[1]Sun WH, et al. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent. J Pharmacol Exp Ther. 2000 Nov;295 (2) :447-52.|[2]Tanigawa T, et al. Rebamipide inhibits gastric cancer cell growth. Dig Dis Sci. 2007 Jan;52 (1) :240-7.